1h Free Analyst Time
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin. Speak directly to the analyst to clarify any post sales queries you may have.
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 6 respectively. Report covers products from therapy areas Metabolic Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Musculoskeletal Disorders, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Porphyria (Erythropoietic Protoporphyri), Uveitis, Vitiligo, Acne Vulgaris, Acute Ischemic Stroke, Choroidal Neovascularization, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, IgA Nephropathy (Berger's Disease), Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Multiple Sclerosis, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Pulmonary Fibrosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Ulcerative Colitis and Unspecified Dermatological Disorders.
The latest report Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2022, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
- Clinuvel Pharmaceuticals Ltd
- Mallinckrodt Plc
- Mitsubishi Tanabe Pharma Corp
- Palatin Technologies Inc
- SynAct Pharma AB
- Viewpoint Molecular Targeting LLC
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
- afamelanotide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AP-1189 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- corticotropin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CUV-9900 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dersimelagon phosphate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Next Generation of Compounds - Drug Profile
- Product Description
- Mechanism Of Action
- Parvysmelanotide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-8177 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-8331 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-9643 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PL-9654 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VMT-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
- Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
- Featured News & Press Releases
- Jun 29, 2022: SynAct Pharma recieves pre-IND response from the US FDA
- Jun 22, 2022: SynAct Pharma submits CTA for clinical phase 2b study in RA
- May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
- May 10, 2022: Clinuvel progresses vitiligo study
- May 09, 2022: CLINUVEL progresses vitiligo treatment program
- May 04, 2022: CLINUVEL Pharmaceuticals : Positive final results in stroke
- May 04, 2022: SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet
- May 02, 2022: Palatin to present on PL9643 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
- May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
- May 02, 2022: Palatin to present on PL8177 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
- Apr 21, 2022: Palatin to present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS) 2022
- Mar 15, 2022: Afamelanotide in stroke (AIS) - Positive preliminary results
- Mar 03, 2022: Palatin hosting key opinion leader webinar on dry eye disease
- Feb 14, 2022: CLINUVEL expands DNA repair program with 2nd DNA repair study
- Jan 22, 2022: SCENESSE continued in Germany
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
- Pipeline by Mallinckrodt Plc, 2022
- Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
- Pipeline by Palatin Technologies Inc, 2022
- Pipeline by SynAct Pharma AB, 2022
- Pipeline by Viewpoint Molecular Targeting LLC, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Clinuvel Pharmaceuticals Ltd
- Mallinckrodt Plc
- Mitsubishi Tanabe Pharma Corp
- Palatin Technologies Inc
- SynAct Pharma AB
- Viewpoint Molecular Targeting LLC
